Literature DB >> 6402518

Acetamide broth for isolation of Pseudomonas aeruginosa from patients with cystic fibrosis.

N M Kelly, F R Falkiner, C T Keane.   

Abstract

The recovery of Pseudomonas aeruginosa was enhanced by incubating specimens in acetamide broth before subculture on cetrimide agar. This finding is of particular value in screening pediatric patients with cystic fibrosis for carriage of P. aeruginosa.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6402518      PMCID： PMC272593          DOI： 10.1128/jcm.17.1.159-.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  4 in total

1.  Evaluation of culture media for the isolation and enumeration of Pseudomonas aeruginosa.

Authors:  C H Drake
Journal:  Health Lab Sci       Date:  1966-01

2.  Identification of Pseudomonas aeruginosa in the clinical laboratory.

Authors:  I Phillips
Journal:  J Med Microbiol       Date:  1969-02       Impact factor: 2.472

3.  Use of acetamide broth in the isolation of Pseudomonas aeruginosa from rectal swabs.

Authors:  R F Smith; S L Dayton
Journal:  Appl Microbiol       Date:  1972-07

4.  Mucoid Escherichia coli in cystic fibrosis.

Authors:  A B Macone; G B Pier; J E Pennington; W J Matthews; D A Goldmann
Journal:  N Engl J Med       Date:  1981-06-11       Impact factor: 91.245
  4 in total
  7 in total

1.  Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis.

Authors:  D P Speert; S W Farmer; M E Campbell; J M Musser; R K Selander; S Kuo
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

2.  Use of a pilin gene probe to study molecular epidemiology of Pseudomonas aeruginosa.

Authors:  D P Speert; M E Campbell; S W Farmer; K Volpel; A M Joffe; W Paranchych
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

3.  Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets.

Authors:  G Döring; H Bareth; A Gairing; C Wolz; K Botzenhart
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

4.  Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.

Authors:  L T Weaver; M R Green; K Nicholson; J Mills; M E Heeley; J A Kuzemko; S Austin; G A Gregory; A E Dux; J A Davis
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

5.  New selective medium for Pseudomonas aeruginosa with phenanthroline and 9-chloro-9-[4-(diethylamino)phenyl]-9,10-dihydro-10- phenylacridine hydrochloride (C-390).

Authors:  M E Campbell; S W Farmer; D P Speert
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

6.  Fecal isolation of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  U Agnarsson; S Glass; J R Govan
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

7.  Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis.

Authors:  R F Taylor; D W Morgan; P S Nicholson; I S Mackay; M E Hodson; T L Pitt
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.